The rapidity of response to induction therapy is emerging as an important prognostic factor in children and adolescents with acute lymphoblastic leukemia (ALL). We studied the relationship between rapidity of reduction in peripheral blood blast count and treatment outcome in children with T cell ALL (T-ALL). Initial systemic chemotherapy included prednisone, vincristine, doxorubicin and cyclophosphamide. A Cox analysis evaluated the correlation between the length of time that the peripheral blood absolute blast count (ABC) remained above 1000/mm 3 following the start of treatment and event-free survival (EFS). Data were available for 281 patients. Patients for whom the ABC remained Ͼ1000/mm 3 for 3 or more days following administration of intensive therapy had an estimated 5-year EFS of 34.2% (s.e. = 7.2) vs 58.3% (3.5) for those whose ABC was Ͻ1000/mm 3 within 0-2 days, with a hazard ratio (HR) of failure of 2.03 (95% CI = 1.35-3.06, P Ͻ 0.001) for the slower responding patients. Pre-treatment of some type (usually with prednisone) occurred in 128 patients (average duration 1.7 days). When this was accounted for, patients with an ABC Ͼ1000/mm 3 for 5 or more days following the start of treatment of any kind had a HR for failure of 2.27 (95% CI = 1.38-3.72, P Ͻ 0.001) compared to those responding within 0-4 days. Inclusion of other clinical and biological factors in a multivariate analysis did not alter the prognostic importance of slower blast clearance. Pediatric patients with T-ALL who have a circulating blast count Ͼ1000/mm 3 at diagnosis and a relatively slower response to initial treatment are at increased risk of treatment failure. Rapidity of response may therefore be a clinically useful prognostic factor for patients with T-ALL. Leukemia (2000) 14, 792-795.
Introduction
Risk-directed therapy of childhood acute lymphoblastic leukemia (ALL) has been facilitated by the delineation of pre-treatment clinical and biological factors that are predictive of treatment outcomes. [1] [2] [3] The rapidity of cytolytic response following the initiation of induction chemotherapy in childhood ALL is another prognostic factor. Studies which evaluated the percentage of leukemic blasts present in the bone marrow following 7 or 14 days of treatment have shown that patients with slower early response to treatment have a significantly higher risk of treatment failure. [4] [5] [6] [7] In some patients this adverse prognostic factor can be abolished by intensification of therapy. 8 The rapidity of disappearance of blasts from the peripheral blood after initiation of treatment has also been studied. Inferior outcome was observed in patients with a slow response to either 7 days of steroid monotherapy [9] [10] [11] or following multi-agent chemotherapy. 12, 13 peripheral blood blasts has also been associated with poorer survival in adults with ALL.
14 Leukemia of T cell immunophenotype (T-ALL) has unique clinical and biological features and generally a less favorable prognosis. 15 In contrast to ALL of B cell precursor immunophenotype, few factors consistently delineate patients with T-ALL who have a more or less favorable prognosis. [16] [17] [18] [19] However, reports that analyzed the relationship between rapidity of response to treatment and durability of remission in patients with T-ALL have suggested that rapidity of response is also prognostically significant in that subgroup. 11, 13 Pediatric Oncology Group (POG) protocol 8704 and its pilot predecessor protocol 8691 provided an opportunity to further explore the relationship between rapidity of response to treatment and outcome in T-ALL.
Patients and methods

Patient selection
Patients were enrolled on POG studies 8691 and 8704. The former was a pilot study which preceded the subsequent randomized evaluation of intensive asparaginase therapy given in conjunction with a backbone of multi-agent chemotherapy. Details of the treatment and results were published by Amylon et al. 20 A total of 448 eligible patients with newly diagnosed T-ALL were entered on to these protocols between January 1986 and January 1992.
Data sheets submitted to the study coordinator for each patient were retrospectively examined for complete blood count (CBC) and differential count values during the first week of treatment. For each day, an 'absolute blast count' (ABC) was calculated by multiplying the total leukocyte count by the percentage of blasts reported in the differential count and dividing by 100. To be consistent with previously published studies, 9-11 a target response of 1000 blasts/mm 3 was employed. The rapidity of response for each patient was defined as the number of days that the ABC remained Ͼ1000/mm 3 following initiation of treatment. Eligible patients were excluded from analysis if the initial ABC was below 1000/mm 3 or if no CBC results were recorded. Although most patients had daily CBCs, some did not, so the precise day that the ABC fell below 1000/mm 3 could not always be determined. When this occurred, an imputed figure was assigned which was the average of the 2 days for which data were available that bracketed the day that the ABC must have reached the target threshold.
The dates of administration of chemotherapy and any deviations from the protocol guidelines were noted. As described below, the protocol called for combination chemotherapy on day 1. In practice, however, the guidelines were not always followed. For instance, prednisone and/or vincristine pretreatment were given to some patients from 1 to several days prior to the initiation of the other agents. To account for this, the rapidity of response to therapy was analyzed from two time points. The first was from the day of cyclophosphamide administration. The second was from the day of administration of treatment of any kind. 
Treatment
Statistical methods
The primary question evaluated was whether or not there was an association between failure and time to ABC Ͻ1000/mm 3 (1) from the start of administration of cyclophosphamide and (2) from the start of any therapy. This was analyzed by two Cox regressions 21 with independent variables the number of days (1 or 2) and treatment. If either of these analyses produced a P value below 5%, a forward stepwise analysis 22 of the specific significant variable would follow to look at the significance of various cut points: 0 vs 1 + days, 0-1 vs 2+ days, 0-2 vs 3+ days, etc. The initial Cox regressions were conducted to control for spurious associations inherent in multiple cut points. Each of the stepwise analyses also included L-asparaginase treatment assignment as a covariate. Actuarial event-free survival estimates were constructed by the method of Kaplan and Meier 23 with standard errors of Peto et al. 24 Failure was defined as either relapse, death, or development of second cancer. Only six patients had events not due to primary disease (one toxic death and five second cancers) and analysis by competing risks was not performed. This paper presents data to the cutoff of April 1997, the time point where all patients had been at risk for at least 5 years. As of December 1998, no additional failures have been reported, and the updated results are consistent with those reported herein. However, we elect to report the earlier results as more representative of the process of reaching the conclusions.
Results
Study population
A total of 448 eligible patients with T-ALL were enrolled on POG protocols 8691 and 8704. Of these, 70 (15.7%) had an absolute blast count (ABC) Ͻ1000/mm 3 at the time of diagnosis and could not be assessed for the target response. An additional 97 patients (21.6%) had insufficient data to assess the reduction in ABC in the peripheral blood during the week following initiation of therapy. Stratified for treatment regimen (control vs intensive asparaginase), event-free survival (EFS) was not different between patients with and without interpretable ABC data (P = 0.62 by two-sided log rank analysis).
Data could be evaluated for 281 patients. One hundred and fifty-three patients received therapy as stipulated by the protocol guidelines (therapy instituted with all agents starting on Leukemia Patients with longer periods of time that the absolute blast count remained Ͼ1000/mm 3 following administration of cyclophosphamide were at significantly increased risk of treatment failure. day 1), and 128 patients received pre-treatment prior to the administration of cyclophosphamide. The mean duration of pre-treatment was 1.7 days (range 1-5 days).
Cox analysis for treatment failure
The results of the Cox analyses comparing the rapidity of response to treatment outcome are shown in Tables 1 and 2 . Patients for whom the ABC remained above 1000/mm 3 for longer periods of time were found to be at a significantly increased risk of treatment failure than those who experienced a more rapid reduction in peripheral blast count. This correlation was significant whether the treatment start date was defined as the date of administration of cyclophosphamide or whether the data were analyzed from the start of pre-treatment. For instance, for two patients A and B receiving the same treatment, with A taking 3 days longer to respond from the start of cyclophosphamide than B, at equivalent times from registration, patient A had an estimated instantaneous risk of failure 1.43 times that of patient B (95% confidence from 1.16 to 1.77).
Stepwise Cox analysis
Forward stepwise analyses were conducted to assess cut points for significance, with the results shown in Table 3A and B. For treatment defined as starting upon administration of cyclophosphamide, the subdivision of 0-2 vs 3+ days was the most significant (see Table 3A ). No further subdivision, adjusted for asparaginase arm treatment, resulted in statistical significance; 0-4 vs 5+ days was closest at P = 0.14. Using the day of administration of any therapy as treatment start date, 0-4 vs 5+ days (Table 3B ) was the most significant subdivision. No further subdivision, adjusted for treatment, resulted in stat- Patients with longer periods of time that the absolute blast count remained Ͼ1000/mm 3 following administration of therapy of any kind were at significantly increased risk of treatment failure. Patients whose absolute blast count remained Ͼ1000/mm 3 for 3 or more days after receiving cyclophosphamide had a significantly increased risk of treatment failure. Patients whose absolute blast count remained Ͼ1000/mm 3 for 5 or more days after receiving therapy of any kind had a significantly increased risk of treatment failure. istical significance; 0-6 vs 7+ days was next closest at P = 0.38. An analysis that excluded the cases that required use of the imputed figure to calculate the time to reach an ABC Ͻ1000/mm 3 yielded similar results. Table 4 presents KaplanMeier EFS estimates at various time points for the subgroups.
Multivariate stepwise Cox analysis
Other clinical and biological factors (age, gender, race, initial leukocyte count Ͼ or Ͻ50 000/mm 3 , CD10 positivity, and blast maturation stage (mid vs early + late)) were included in a multivariate analysis of outcome in relation to rapidity of blast count reduction. Inclusion of these factors in the analysis (data not shown) did not affect the conclusions about the prognostic significance of reduction in peripheral blast count following treatment.
Discussion
The current study represents the largest cohort of T cell ALL patients yet studied for the prognostic importance of early Table 4 Kaplan-Meier estimates (s.e.) of event-free survival for subgroups
From first cyclophosphamide From any therapy 0-2 days 3+ days 0-4 days 5+ days n = 229 n = 52 n = 247 n = 34 a Only three censored patients were followed fewer than 5 years.
response, and extends the findings of previous investigations by seeking to delineate the time point where slower response was most prognostic. Some previous studies that examined this phenomenon have employed a 7 day corticosteroid treatment window to assess early response, including those of the BFM group 9,10 and Arico et al. 11 The latter report studied 184 children with T-ALL and found that patients whose peripheral blast count was Ͻ1000/mm 3 within a week achieved a 60.3% EFS, while the EFS was 43.5% for patients with a blast count Ͼ1000/mm 3 after a week of steroid monotherapy. More recently, Gajjar et al 13 found that the presence of blasts in any quantity in the peripheral blood 7 days after the initiation of a multi-agent induction regimen (vincristine, prednisone, Lasparaginase plus daunorubicin or teniposide/cytarabine) was associated with a less favourable outcome in 56 patients with T-ALL. More rapidly responding patients had an EFS of 64% vs 39% for the slower responders. Although the initial and subsequent therapies, as well as methodology used to assess rapidity of response, are quite different in our study compared to those of Arico and Gajjar, the results obtained are intriguingly similar.
A number of methods other than blast disappearance from the peripheral blood have been used to assess rapidity of response in relationship to treatment outcome. Some studies evaluated the response to induction therapy by assessing the degree of residual leukemic infiltration in the bone marrow following 7 or 14 days of chemotherapy. [4] [5] [6] [7] Repeated bone marrow aspirations during induction therapy to assess response, however, subject the patient to additional painful procedures and expose them to risks of infection and bleeding as well. Thus, it would be advantageous if equally useful information could be obtained by the careful examination of peripheral blood counts during the first few days of therapy. Recent reports studying minimal residual disease quantitation using a variety of sophisticated techniques have also reported intriguing correlations between the degree of cytoreductive response and outcome. 25, 26 The relative merits of different methodologies for assessing the prognostic value of rapidity of early response deserve further comparative study.
The induction treatment used in the POG protocols evaluated in the current study was different than that typically used for children with ALL. In addition to administration of prednisone, vincristine, and doxorubicin, a moderately high dose of cyclophosphamide was given at the outset of induction therapy. Nonetheless, it was still possible to identify response time points following onset of treatment that were prognostically important. As might be expected, the use of a slightly more intensive initial treatment shortened the time frame within which this response occurred.
The current study was retrospective in nature, and hence data could not be obtained for all patients. In addition, using a methodology that excluded patients with an ABC Ͻ1000/mm 3 pre-selected patients with higher white counts (the median for patients with adequate data was 112 000/mm 3 vs 22 000/mm 3 for patients without data or with low initial ABC). Gender, age distribution, and EFS, however, were similar for the two patient groups.
A large number of pre-treatment clinical and biological factors have been identified that are of prognostic importance in pediatric ALL. However, relatively few consistent prognostic factors have been identified for patients with T-ALL. Immunophenotypic characteristics have been shown to delineate prognostic groups in T-ALL but the differences were neither large nor consistent. [17] [18] [19] Our data suggest that rapidity of blast response to initial chemotherapy may separate patients with T-ALL into groups with highly different risks of treatment failure.
In our study, even patients with a more rapid response had an EFS Ͻ60%, emphasizing the point that all T-ALL patients warrant intensive treatment. In the future, however, evaluation of rapidity of response may eventually allow tailoring of treatment to the risk of disease recurrence rather than treating all children with T-ALL with increasingly intensive regimens.
